BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

May 27, 2021

Announcement no. 12



Managers’ transactions

BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them.

1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Thomas Magnussen
2. Reason for the notification  
a) Position/status Chairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.78, Volume: 60,227
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-25
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE



1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Therazone ApS
2. Reason for the notification  
a) Position/status Closely associated person to Thomas Magnussen, Chairman of the Board of Directors of BioPorto A/S



 
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.78, Volume: 191,621
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-25
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE



1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Thomas Magnussen
2. Reason for the notification  
a) Position/status Chairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.52, Volume: 128,344
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-26
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE



1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Therazone ApS
2. Reason for the notification  
a) Position/status Closely associated person to Thomas Magnussen, Chairman of the Board of Directors of BioPorto A/S



 
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.52, Volume: 408,379
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-26
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

For further information, please contact:

Karen Stendal, Legal Counsel

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

 

Attachment



EN
27/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voks...

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off 31. marts, 2026Meddelelse no. 6 BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off KØBENHAVN, DANMARK, 31. marts, 2026 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH: BIOPOR) meddelte i dag, at de formelt har indsendt deres FDA Pre-submission pakke til den amerikanske Food and Drug Administration (FDA). Dette markerer en vigtig regulatorisk milepæl for Selskabet ...

 PRESS RELEASE

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submissio...

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary an...

 PRESS RELEASE

Indkaldelse til ordinær generalforsamling i BioPorto A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S 26. marts 2026Selskabsmeddelelse nr. 5 Indkaldelse til ordinær generalforsamling i BioPorto A/S Bestyrelsen indkalder hermed til ordinær generalforsamling i BioPorto A/S ("BioPorto" eller "Selskabet"), som afholdes: 24. april 2026 kl. 15.00på Selskabets adresseTuborg Havnevej 15, st., 2900 Hellerup, Danmark DAGSORDEN: PUNKT 1 - BERETNING OM SELSKABETS VIRKSOMHED I DET FORLØBNE ÅR Bestyrelsen foreslår, at bestyrelsens beretning om Selskabets virksomhed i det forløbne år tages til efterretning. PUNKT 2 – FREMLÆGGELSE AF ÅRSRAPP...

 PRESS RELEASE

Notice convening the Annual General Meeting in BioPorto A/S

Notice convening the Annual General Meeting in BioPorto A/S 26 March 2026Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: 24 April 2026 at 3.00 p.m. (CEST)at the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for the past year be noted. ITEM 2 – PRESENT...

 PRESS RELEASE

BioPorto annoncerer Årsrapporten for 2025

BioPorto annoncerer Årsrapporten for 2025 26. marts 2026Meddelelse nr. 04                                                                                                                                                                                                BioPorto annoncerer årsrapporten for 2025 København, Danmark, 26. marts 2026 (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller selskab) (CPH:BIOPOR) offentliggjorde i dag de finansielle resultater for året 2025. De finansielle resultater for 2025 bekræfter de foreløbige, ureviderede finansielle tal for 202...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch